{"slideshow_credits": null, "snippet": "The Food and Drug Administration has approved Sovaldi, from Gilead Sciences, which will let some patients be treated for a minimum of 12 weeks, but at a cost of $1,000 per daily pill.", "abstract": "Food and Drug Administration approves Sovaldi, from Gilead Sciences, pill that is expected to make treatment of hepatitis C less onerous, shorter in duration and more effective; pill will allow some patients with liver-destroying virus to do away with weekly injections and debilitating side effects.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/12/07/business/fda-approves-pill-to-treat-hepatitis-c.html", "lead_paragraph": "The Food and Drug Administration has approved Sovaldi, from Gilead Sciences, which will let some patients be treated for a minimum of 12 weeks, but at a cost of $1,000 per daily pill.", "headline": {"main": "F.D.A. Approves Pill to Treat Hepatitis C", "print_headline": "New Hope In Hepatitis As F.D.A. Allows Pill"}, "_id": "52a27cbb38f0d8051b44be8a", "word_count": "1004", "multimedia": [{"height": 126, "url": "images/2013/12/07/business/07hepatitis-span/07hepatitis-span-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/12/07/business/07hepatitis-span/07hepatitis-span-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2013/12/07/business/07hepatitis-span/07hepatitis-span-articleLarge.jpg", "legacy": {"xlarge": "images/2013/12/07/business/07hepatitis-span/07hepatitis-span-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/12/07/business/07hepatitis-span/07hepatitis-span-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/12/07/business/07hepatitis-span/07hepatitis-span-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-12-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Liver", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Hepatitis", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Gilead Sciences Inc", "name": "organizations", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}